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Abstract
Cell cultures and cell lines are widely used in life science experiments. In conjunction with the 2018 International
Conference on Biomedical Ontology (ICBO-2018), the 2nd International Workshop on Cells in ExperimentaL Life
Science (CELLS-2018) focused on two themes of knowledge representation, for newly-discovered cell types and for
cells in disease states. This workshop included five oral presentations and a general discussion session. Two new
ontologies, including the Cancer Cell Ontology (CCL) and the Ontology for Stem Cell Investigations (OSCI), were
reported in the workshop. In another representation, the Cell Line Ontology (CLO) framework was applied and
extended to represent cell line cells used in China and their Chinese representation. Other presentations included a
report on the application of ontologies to cross-compare cell types and marker patterns used in flow cytometry
studies, and a presentation on new experimental findings about novel cell types based on single cell RNA sequencing
assay and their corresponding ontological representation. The general discussion session focused on the ontology
design patterns in representing newly-discovered cell types and cells in disease states.
Introduction
The rapid advancement of cell technologies has inevit-
ably led to challenges in keeping up with the volume of
the data being produced as well as the dynamic evolu-
tion of data formats and knowledge representation. Ex-
perimental cell cultures and cell lines are widely used
and often generated de novo as part of an experimental
protocol, while normalization of experimental cell data
produced in different laboratory settings is difficult due
to the non-synchronous nature of multiple laboratories
working on similar questions on the same timeline. New
knowledge obtained by high-resolution technologies
(e.g., mass cytometry or single-cell RNA sequencing)
adds more data volume that requires robust analysis and
representation, especially regarding novel cell popula-
tions that do not correspond to existing classes of the
community-based Cell Ontology (CL) [1] or Cell Line
Ontology (CLO) [2], two cell-related reference ontol-
ogies in the Open Biomedical Ontology (OBO) frame-
work [3].
The first International Workshop on Cells in Experi-
mentaL Life Science (CELLS-2017) was held in Newcastle,
UK, on September 2017 on the theme of identifying chal-
lenges from the ontology semantic perspective, and the
experimental laboratory perspective [4]. The CELLS-2017
workshop included 7 oral presentations, and eventually
five full-length articles [5–9] were published in the special
issue of the first CELLS workshop in BMC Bioinformatics
(https://bmcbioinformatics.biomedcentral.com/articles/
supplements/volume-18-supplement-17).
Following the success of the first CELLS workshop,
the 2nd International Workshop on Cells in Experi-
mentaL Life Science (CELLS-2018) was held on August
7, 2018, in conjunction with International Conference
on Biomedical Ontology 2018 (ICBO-2018), August 7–
10, 2018, Corvallis, Oregon, USA. CELLS-2018 was or-
ganized with a focus on the themes of addressing the
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challenges of knowledge representation of newly-discovered
cell types and of cells in disease states.
Summary of the talks and papers presented at
this workshop
The half-day CELLS-2018 workshop included five oral
presentations and a general discussion session. Four of
the proceedings papers, corresponding to four oral pre-
sentations, have been extended, further reviewed, and
are published in this special issue for the CELLS-2018
workshop in BMC Bioinformatics.
In this workshop, two new ontologies were reported.
Serra et al. presented the development of the Cancer Cell
Ontology (CCL) that represents cancer cell types related to
a variety of hematologic malignancies using logical axioms
that capture the expression of cellular surface markers
using Protein Ontology (PRO) [10] classes [11]. The ontol-
ogy includes human and computer-readable definitions for
300 classes of blood cancers. The logical axioms of the
ontology can be used to classify patient cell surface marker
data into appropriate diagnostic categories, to allow for in-
tegration of the ontology into existing tools for flow cytom-
etry data analysis to facilitate the automated diagnosis of
hematologic malignancies.
The other reported new ontology is the Ontology for
Stem Cell Investigations (OSCI) [12]. Stem cells and stem
cell lines have been widely used in biomedical research. CL
and CLO represent in vivo stem cells and in vitro stem cell
line cells, respectively. However, neither CL nor CLO has a
focus on the representation of stem cell investigations,
which is the main goal of the community-driven OSCI
ontology. OSCI imports stem cell and stem cell line related
classes from CL and CLO. OSCI also imports classes
needed to describe stem cells and stem cell experi-
mental methods from other ontologies such as PRO
[10] and the Ontology for Biomedical Investigations
(OBI) [13] . Many metadata types associated with
various stem cell investigations have been identified and
represented as classes in OSCI. Two use cases of OSCI in-
clude applying OSCI to systematically explore experimen-
tal variables in induced pluripotent stem cell line cell
studies related to bipolar disorder, and applying OSCI to
model and represent stem cell gene markers and relations
identified using semi-automated literature mining.
The Chinese National Infrastructure of Cell Line Re-
source (NICR) stores and distributes over 2000 cell lines in
China. To support worldwide interoperable cell line infor-
mation representation and usage, Pan et al. reported the
development of CLO-NICR ontology that represents these
cell lines using the semantic framework of CLO [14]. As a
subset of the master CLO release, CLO-NICR can also be
used in a stand-alone way to support applications for bio-
medical research in China NICR. A new ontology design
pattern specifically to CLO-NICR is proposed to bridge cell
line cells to disease studies using laboratory animal models.
The authors also demonstrate the Chinese language repre-
sentation of the cell line cell information. The CLO-NICR
development was one of the research efforts from the
OntoChina (http://www.ontochina.org) [15], a new initia-
tive supporting an ontology developer community program
in China to promote collaborative ontology development
and applications around the world.
In flow cytometry, cells are gated into different popu-
lations based on common features like forward or side
scatter or expression patterns of protein markers. The
cell populations are typically identified via a general
name of the cell type (e.g. ‘T cells’) and the specific
marker pattern observed (e.g. CD14−/CD3+). In a
CELLS-2018 presentation, Vita et al. applied ontologies
to connect cell population descriptions and gating defi-
nitions [16]. In their study, ontologies were used to
cross-compare cell types and marker patterns in the
ImmPort Immunology Database and Analysis Portal
[17]. The gating definitions were parsed using classes
from the Cell Ontology (CL) [1] and the Protein Ontol-
ogy (PRO) [10]. Logical axioms in the CL were used to
detect discrepancies between submitted data about cell
populations and cell type classes in the CL. New OBI
classes were also generated to describe and capture data
acquisition. This study resulted in suggestions for new
logical axioms and cell types for addition to the CL.
One challenge is how to ontologically represent the cell
types newly discovered using experimental technologies.
In a CELLS-2018 podium presentation, Mohamed Keshk
of Richard H. Scheuermann’s group presented a
provisional cell type ontology that represents newly identi-
fied novel cell types experimentally identified using single
cell RNA sequencing (scRNAseq), an extension of the
work Dr. Scheuermann’s group presented in the
CELLS-2017 workshop [5]. The data being gathered from
the experimental work is represented in a standard seman-
tic format that can be exchanged, retrieved, and inferred
over using standard approaches and tools. This format
supports the translation and representation of biological
knowledge to become findable, accessible, interoperable
and reproducible (FAIR), per the FAIR principles [18].
As can be seen, the presentations at the CELLS-2018
workshop covered a range of issues in the representation
of cell types: cell types and experimental methodology
related to them from under-represented domains includ-
ing cancer cells and stem cells, the ontological represen-
tation of cell lines from a major national resource in
China, and the challenge of representing experimental
results about cells based on flow cytometry or single cell
RNA sequencing. If there is a common theme to these
efforts, it is the drive to present a coherent ontological
representation of existing and new knowledge about
cells that builds upon existing efforts in the CL, CLO,
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and OBI, and is likewise extensible for the representa-
tion of new data and methodology related to cell types,
within the OBO Foundry framework.
Challenges and opportunities
In the CELLS-2018 workshop, we also organized a
general discussion session. Our discussion focused on
the design pattern representation of normal vs diseased
conditions in cells. For example, what is the difference
between normal and diseased cells, and how to onto-
logically represent the transformation from a normal cell
to diseased cell, and what are the common design
patterns for normal and diseased cells? In addition, we
discussed how to represent additional information (e.g.,
gene markers) in ontology? The five presentations
described above fit in well with the discussion theme.
One challenge in cell ontology development is to how
to specify the definition of cell types. The de facto con-
vention used for the creation of many classes in the CL
has resulted in the creation of cell type classes that are
named and defined both textually and logically by the
cell surface markers expressed by the cell type using a
post-composed approach. This is may be less than ideal
as the community discovers new cell types based on
subdividing known cell populations with additional
markers. As we move beyond marker definition of cell
types developed via flow cytometry to defining cell types
via single cell RNA sequencing or proteomics, a cell type
could potentially be defined by a combinations of hun-
dreds of marker genes or proteins. Should we add more
markers to cell types and use these markers for cell type
definitions? As reflected by the work of Dr. Scheur-
mann’s group and others [19], we might therefore con-
sider what constitutes the minimal combination set of
markers that can uniquely define a new cell type? Under
some circumstances, defining cell types by cell surface
or internal markers may not be sufficient. For example,
to define brain cells, we may also need to include other
physiological and morphological properties such as cell
location and function in order to uniquely define a spe-
cific brain cell type. However, in many older experimen-
tal protocols, all the cells of a given tissue are
homogenized prior to RNA or protein extraction, result-
ing in the loss of specific location and function informa-
tion in the process. Other types of experiment rely on,
for instance, immunofluorescence or green fluorescence
protein (GFP) tagging to examine the expression and
localization of protein markers in cells. Given the diver-
sity of the experimental approaches for studying cells,
we need to be careful in how we represent experimental
results in the form of ontological definitions of cell
types. Some results may be true under specific experi-
mental conditions, such as during cellular activation;
however, under other conditions, the results may not be
true or may only be true for a particular state of a cell
type. Ontology classes should always represent certainty,
and not probability. Definitive identification and represen-
tation of cell types requires synthesizing knowledge gained
from multiple experimental approaches for a cell type def-
inition to be accepted as truth. Another question is how
to infer cell function. How can we ontologically represent
cell function and related pathways in normal or diseased
cells? Can we infer the function by merging cell morph-
ology and gene expression? Can we use function analysis
via, for instance GO term enrichment of expressed genes
to identify key biological processes a cell may be partici-
pating in, and thereby establish a functional signature that
can be used to infer cell type? These questions may need
to be addressed outside an ontology class level. Solutions
under discussion include inference via instances of the
main class, or using other object/annotation properties to
build the inferred knowledge.
As the basic unit of life, the cell remains central to bio-
logical and biomedical research. Given that challenges
presented by studies of cells and their ontological repre-
sentation and applications, the attendees of the workshop
welcome and expect more CELLS workshops in the fu-
ture. And, of course, these challenges in themselves are
also opportunities. For example, the Human Cell Atlas
project, which aims to map all the cells in the human
body, has recently been initiated from vision to reality
[20], and is already generating a wealth of data about cell
types. Many precision medicine studies, such as the Kid-
ney Precision Medicine Project (KPMP: http://kpmp.org),
aim to understand specific cell-disease associations and
guide the control and treatment of diseases under differ-
ent clinical conditions [21]. A variety of recent studies
have discovered many new cell types, which sometimes
show different characteristics in normal or disease states
[22–26]. These clinical, experimental, and disease condi-
tions, as well as new knowledge about cell types, need
more in-depth ontological modeling, representation, and
analysis. New tools are also needed to support more pro-
ductive ontological research in the cell field, including the
development of machine learning methods that work
across many data sets to identify necessary and sufficient
criteria for cell type definitions across the whole body. We
anticipate promising research progress in the cell-related
ontology field in the years to come.
Conclusion
The CELLS-2018 workshop provided a venue for re-
searchers to report their updates and new studies, and
to discuss challenges and innovative solutions in the de-
velopment and application of biomedical ontologies to
represent and analyze in vivo and in vitro cell- and cell
line-related knowledge and data, including stem cell
technologies.
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